Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
Cash Interest Paid
Zealand Pharma A/S
Cash Interest Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cash Interest Paid
kr24m
|
CAGR 3-Years
94%
|
CAGR 5-Years
48%
|
CAGR 10-Years
28%
|
|
|
Genmab A/S
CSE:GMAB
|
Cash Interest Paid
kr35m
|
CAGR 3-Years
43%
|
CAGR 5-Years
12%
|
CAGR 10-Years
80%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cash Interest Paid
€15.2m
|
CAGR 3-Years
102%
|
CAGR 5-Years
84%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cash Interest Paid
kr32.2m
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
23%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Cash Interest Paid
kr381k
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
13%
|
|
|
Saniona AB
STO:SANION
|
Cash Interest Paid
kr5.9m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
65%
|
CAGR 10-Years
65%
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
What is Zealand Pharma A/S's Cash Interest Paid?
Cash Interest Paid
24m
DKK
Based on the financial report for Dec 31, 2024, Zealand Pharma A/S's Cash Interest Paid amounts to 24m DKK.
What is Zealand Pharma A/S's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 10Y
28%
Over the last year, the Cash Interest Paid growth was -5%. The average annual Cash Interest Paid growth rates for Zealand Pharma A/S have been 94% over the past three years , 48% over the past five years , and 28% over the past ten years .
You don't have any saved screeners yet